Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.

Journal Article (Journal Article;Review)

PURPOSE OF REVIEW: HER2-targeted therapies have led to improved clinical outcomes in early and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted therapy in early and advanced BC, our current knowledge of cardiotoxicity of novel HER2-targeted therapies, and propose a cardiac monitoring (CM) strategy for this population. RECENT FINDINGS: Long-term data from studies with HER2-targeted therapy in the adjuvant setting have failed to demonstrate an increase in cardiotoxicity over time, and rates of cardiotoxicity seen with novel HER2 agents remain low. Despite over a decade of experience with HER2-targeted therapy, CM in clinical practice is inconsistent in patients with early BC and almost non-existent in advanced BC. Long-term follow-up of clinical trials with HER2-targeted agents in early and advanced BC has failed to demonstrate increased rates of cardiotoxicity over time, attesting to the long-term safety of this class of drugs for the majority of patients, although the long-term cardiac safety of newer HER2 agents in the non-clinical trial setting is largely unknown. We propose CM incorporating clinical history, cardiac imaging, and biomarkers.

Full Text

Duke Authors

Cited Authors

  • Dent, SF; Morse, A; Burnette, S; Guha, A; Moore, H

Published Date

  • August 27, 2021

Published In

Volume / Issue

  • 23 / 11

Start / End Page

  • 128 -

PubMed ID

  • 34453232

Pubmed Central ID

  • PMC8395382

Electronic International Standard Serial Number (EISSN)

  • 1534-6269

Digital Object Identifier (DOI)

  • 10.1007/s11912-021-01114-x


  • eng

Conference Location

  • United States